The global substance use disorder treatment market size is likely to generate sales amounting to USD 40.3 billion in 2024. Over the assessment period from 2024 to 2034, the substance use disorder treatment market CAGR is projected to expand to 5.3% culminating in a market size of USD 67.6 billion by the end of 2034.
Rising prevalence of substance abuse disorders, growing awareness of treatments, increasing supportive government initiatives such as drug awareness campaigns and prevention programs, rising prevalence of opioid use disorders, rising adoption of Nicotine Replacement Therapy (NRT), increasing technological developments in therapies, and a surge in the launch of awareness programs are some of the key factors driving the demand.
The industry is being driven by government attempts to combat drug use problems and the introduction of advantageous regulations. The projects seek to increase access to treatment and support services for substance use disorders.
Surge in number of people seeking treatment as knowledge of substance use disorders grows and attempts to destigmatize addiction. This increases the patient base for drug use disorder treatment providers. The growing use of telemedicine and virtual care creates opportunity to extend access to substance use disorder treatment, particularly in rural areas.
| Attributes | Description |
|---|---|
| Estimated Global Substance Use Disorder Industry Size (2024E) | USD 40.3 billion |
| Projected Global Substance Use Disorder Industry Value (2034F) | USD 67.6 billion |
| Value-based CAGR (2024 to 2034) | 5.3% |
The emergence of personalized medicine techniques for treating substance use disorder, such as pharmacogenomics and biomarker based diagnostics, opens up possibilities for individualized and successful treatment alternatives. Collaborations between treatment providers, pharmaceutical businesses, and technology corporations can accelerate the development of complete and integrated treatments for substance use disorders, opening up new opportunities in the industry.
The combination of holistic and interdisciplinary techniques, such as mental health counseling, peer support, and wellness programs, allows practitioners to provide comprehensive care to those with substance use disorder. The industry faces substantial challenges particularly in emerging nations where the high expense of substance use disorder treatment prevents low income class from accessing the benefits.
Despite this difficulty, the industry remains robust, owing to an increase in government activities and financing aimed at increasing awareness and providing treatment for the long term impacts of substance misuse.
As governments throughout the world step up their efforts to combat substance misuse, the industry is expected to grow significantly. The continued commitment to tackling this public health issue demonstrates the collective efforts to better the lives of those impacted by substance use disorders.
Research that focuses on developing effective interventions to treat substance use disorders and overdoses is supported by the National Institute on Drug Abuse (NIDA). Digital therapeutics, behavioral interventions, and medications can all be included. NIDA continues to strive for the development of treatment strategies that are effective, safe, and desirable.
A herbal and nutritional approach supports natural healing and addressing nutritional imbalances caused by alcohol and drugs. Among the herbs and supplements that support liver health and reduce cravings in individuals with alcohol or opioid use disorder, milk thistle and N-acetylcysteine (NAC) stand out.
Meditation and yoga have been recognized for their potential to support the treatment of SUD. Focused on connecting the mind and body, these practices promote relaxation, stress relief, and emotional balance. Several studies indicate that mind-body therapies can reduce cravings and improve mood while also improving treatment outcomes.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Based on the data in the following table, the global substance use disorder treatment market is expected to exhibit a CAGR from 2024 to 2034. In the first half of the decade (H1) from 2023 to 2033, the CAGR is expected to be 6.3%, declining slightly to 6% in the second half (H2).
| Particular | Value CAGR |
|---|---|
| H1 | 6.3% (2023 to 2033) |
| H2 | 6% (2023 to 2033) |
| H1 | 5.3% (2024 to 2034) |
| H2 | 4.8% (2024 to 2034) |
Over the subsequent period, from H1 2024 to H2 2034, the CAGR is expected to decline gradually to 5.3% in the first half and stay relatively low at 4.8%.
Technological Advancements are likely to Accelerate the Industry Growth
The industry is expected to rise during the forecast period, driven by advances in medical technology, growing addiction prevalence, and increased government efforts to combat addiction. Advances in telemedicine, a greater emphasis on integrated care, and technologically enabled solutions will drive demand. The industry is rapidly developing as a result of rising public knowledge of various therapies and a rise in the prevalence of drug abuse issues.
Over the projected period, beneficial government actions such as drug awareness campaigns and preventative programs are also expected to drive industry growth. The rise in the number of substance use disorders prompted the establishment of substance use disorder treatment. As drug addiction grows increasingly frequent, technological advancements in the diagnostics industry is likely to propel growth.
Development of Telemedicine to Propel Industry Growth
The development of telemedicine, an emphasis on integrated care, an emphasis on patient centered care, and an increased emphasis on technology enabled solutions are some of the key trends. Telemedicine is an important advancement driving the substance use disorder treatment market size.
Integrated care occurs when healthcare practitioners from many professions work together to offer complete treatment for the entire individual. Substance use disorder treatment facilities are increasingly using this approach as this approach enables more holistic therapy. This approach to substance use disorder treatment puts the patient at the center of the treatment process and acknowledges distinct needs of each person. This care approach focuses on building connections with patients and providing them with the tools and knowledge to overcome addiction.
Support Services and Policies to Provide Lucrative Opportunities
A vital component of reducing the prevalence and severity of substance use disorders is advocating for policy changes and increasing access to services. In order to achieve this goal, it is paramount that health insurance policies cover treatments and services necessary for the patient. Maintaining follow-up care and receiving ongoing support are essential for preventing relapse. Regular counseling sessions, self-help programs, and group sessions are some of the ways in which counseling can be provided.
Individuals can maintain long-term sobriety and build a sense of community by utilizing recovery support services such as Narcotics Anonymous and Alcoholics Anonymous. Individuals need support from family and partners to stay on track and cope with treatment. Funding opportunities have been announced by the USA Department of Health and Human Services (HHS) for expanding services for those with substance use disorders. Women in pregnancy and postpartum, as well as adults and families, are the main beneficiaries of these grants. A total of USD 28 million is available for this project.
Stigma Associated with Addiction to Stifle The Industry Growth
The stigma associated with addiction remains a substantial barrier, discouraging people from seeking treatment out of fear of being judged or facing social consequences. Limited access to healthcare services, particularly in rural or underdeveloped regions, exacerbates inequities in treatment availability and cost.
Regulatory constraints and insurance restrictions might impede access to evidence based therapies and drugs, preventing complete care delivery. Insufficient financing for mental health and addiction treatments puts additional strain on resources, restricting the ability of treatment centers and community based programs to fulfill rising demand.
Principal Consultant
Global substance use disorder treatment demand increased at a CAGR of 4.5% from 2019 to 2023. For the next ten years (2024 to 2034), projections are that expenditure on substance use disorder treatment will reach a CAGR of 5.3%.
During the historical period, the industry grew due to the realization of the need of treating addiction as a serious public health issue. Key factors include increased knowledge, improved diagnostic procedures, and the destigmatization of seeking therapy, which encourages more people to seek assistance.
Advances in medical treatments and therapeutic techniques are projected to improve efficacy, making recovery more achievable. Naloxone and buprenorphine, as well as developing medicines, help to manage withdrawal symptoms and reduce relapse rates.
The growing investment in telehealth or digital health companies focused on SUD treatment has transformed access to care, particularly in distant and disadvantaged regions. This innovation not only expands the scope of treatment, but also removes transportation and schedule hurdles, making easier for people to seek continuous care.
Globally, government initiatives and funding for addiction treatment programs play an important role in fostering industry growth. Increased financing for mental health and addiction services, along with supporting legislation, guarantees that more resources are directed at comprehensive treatment programs. Public awareness campaigns help to educate communities about the benefits of early intervention and the availability of various treatment choices.
Collaborations and partnerships in the healthcare business promote a culture of continual development and innovation. Pharmaceutical corporations, healthcare providers, and research organizations collaborate to produce more effective and individualized treatment programs.
As the worldwide society prioritizes mental health and addiction treatment, the industry is expected to grow significantly. This rise not only reflects growing demand, but also demonstrates a shared commitment to fighting the global issue of drug use disorders, thereby enhancing the quality of life for millions of people worldwide.
Among Tier 1 companies, industry leaders account for 55.5% of global market share. Several generics and respiratory product players drive revenue through their strong presence and diverse portfolios. As opioid treatments and continued efforts to address legal liabilities remain crucial to growth, these players will continue to contribute to growth. Growth will be boosted by a strong research & development pipeline over the next few years. Prominent companies within Tier 1 include Purdue Pharma L.P., Indivior plc, and Alkermes plc.
Mid-size companies, with a share of 24.6% in 2024, play a significant role in the regional market. The companies in this category are well-established overseas and possess a deep understanding of the market. Globalization will be aided by advances in technology and therapeutics. Major companies in tier 2 include Mallinckrodt plc, Dr. Reddy’s Laboratories, Glenmark Pharmaceuticals Ltd., Cipla Limited, and Allergan plc.
Tier 3 comprises the majority of small biopharmaceutical companies operating in niche business. Most of these companies are geared towards supplying active pharmaceutical ingredients under the tier 3 share category. Growth will be influenced by smaller companies exploring digital therapies with innovative programs that have lower market penetration.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The following table shows the estimated growth rates of the top three countries. India and China are set to exhibit substantial growth, recording CAGRs of 5.1% and 4.5%, respectively, through 2034.
| Countries | CAGR 2024 to 2034 |
|---|---|
| India | 5.1% |
| China | 4.5% |
| The United Kingdom | 1.6% |
| France | 2.3% |
| The United States | 1.4% |
India is projected to ascend at a CAGR of 5.1% during the forecast period. Increasing awareness and destigmatization are key factors driving the substance use disorder treatment industry in India. Both government and nongovernmental groups have made substantial efforts to improve public awareness about the reality of addiction, emphasizing that this is a medical illness rather than a moral failure. Campaigns emphasizing the need of mental health and addiction therapy have helped to eliminate the stigma associated with seeking help, allowing more people to seek treatment.
Media representing addiction as a curable disorder has normalized getting assistance, while instructional initiatives in schools and workplaces encourage early intervention. Significant personalities and celebrities sharing their recovery stories have helped to improve public opinion, making seeking therapy more socially acceptable.
The above improvements have resulted in a surge in demand for professional SUD treatment services including as counseling, rehabilitation centers, and telemedicine alternatives, which is driving the demand.
The United Kingdom is predicted to augment at a CAGR of 1.6% during the projected period. Telemedicine and virtual care are transforming the substance use disorder treatment sector in the United Kingdom, resulting in considerable growth and accessibility. The impact of COVID-19 on the substance use disorder treatment landscape has pushed the implementation of digital health technologies, stressing the importance of remote treatment alternatives.
The flexibility of telemedicine enables constant involvement with healthcare practitioners, which is important for long term healing. Digital technologies provide real time data tracking, enabling more tailored and adaptable treatment techniques.
Government assistance and legal modifications have aided the incorporation of telemedicine in SUD therapy. Telemedicine is not only improving patient outcomes but also increasing access to appropriate care in rural and underserved regions across the United Kingdom.
The United States is expected to thrive at a CAGR of 1.4% during the assessment period. Collaborations and partnerships are important for advancing the substance use disorder treatment sector in the United States. Pharmaceutical corporations, healthcare providers, and research organizations are increasingly working together to improve treatment alternatives and accessibility. Partnerships between drug makers and rehabilitation clinics, for example, guarantee that medication assisted therapy (MAT) is seamlessly integrated into comprehensive care programs.
Collaborations with technology corporations have also resulted in novel telehealth solutions, increasing access to counseling and behavioral treatments. Public private collaborations are prominent, with government institutions sponsoring research and promoting community based projects.
The above strategic relationships not only promote the discovery of novel treatment modalities, but also expedite care delivery, covering a wide range of patients. By combining their knowledge and resources, stakeholders can better address the layered nature of addiction, eventually improving patient outcomes and driving the demand.
| Segment | Detoxification (Treatment) |
|---|---|
| Value Share (2023) | 36.5% |
The detoxification category showed significant growth in 2023, accounting for 36.5%. Substance-related disorders are treated with detoxification as part of the healthcare continuum. The treatment of individuals suffering from substance use disorders must be administered with the same level of quality and thoroughness regardless of their circumstances. Individuals must receive treatment for substance abuse following detoxification to achieve long-term abstinence.
A detoxification program provides a unique opportunity to intervene during a crisis and encourage people to seek treatment. As part of the detoxification process, it is essential to develop a therapeutic alliance with patients in order to motivate them to continue their treatment process. Treatment outcomes can be improved with supportive and compassionate care, along with medication.
Symptoms of comorbid mental health disorders can be more effectively treated if detoxification is undertaken concurrently with treatment for the comorbid mental health disorders. In addition to substance use disorders, many individuals who suffer from mental health disorders also experience substance use disorders. Managing these comorbid conditions can assist in improving the retention and effectiveness of treatment.
| Segment | Alcohol Abuse Treatment (Type) |
|---|---|
| Value Share (2023) | 51.5% |
In 2023, the alcohol abuse treatment segment led the substance use disorder treatment market, with a share of 51.5%. This growth is a reflection of growing awareness about the alcohol dependency and the availability of specialist treatment choices. The increased use of medication assisted is a key substance use disorder treatment market opportunity.
Leading treatment institutions are improving their programs by combining cognitive behavioral therapy (CBT), counseling, and support groups, resulting in complete care models suited to individual requirements. Advances in telemedicine are increasing access to therapy, particularly in underprivileged regions, allowing more people to seek assistance and further driving the demand for this segment which is likely to increase.
The substance use disorder treatment market is extremely competitive and constantly developing, driven by rising demand for effective treatment options. Pharmaceutical firms, rehabilitation institutions, and specialist clinics provide a variety of therapies, including medication assisted therapy (MAT), behavioral therapies, and holistic methods.
Leading companies in the substance use disorder treatment market are focusing on strengthening their position in the market through mergers and acquisitions activity in the SUD treatment sector. Venture capital or private equity funds targeting innovative SUD treatment options and also making considerable investment in telehealth or digital health companies focused on SUD treatment to ease SUD treatment market risks.
Rehabilitation institutions promote comprehensive therapy, incorporating medical detox, counseling, and aftercare programs. The introduction of telehealth services has created new rivals, such as BetterHelp, which provide remote counseling and assistance. Innovation and regulatory changes have a substantial impact, with continual research into novel drugs and therapeutic procedures improving treatment efficacy.
Recent Developments
The segment is classified into alcohol abuse treatment, nicotine abuse treatment and drug abuse treatment.
Based on treatment type, the industry is classified into detoxification, counseling & behavioral therapy, medication and support group.
Analysis of the substance use disorder treatment market has been carried out in key countries of North America, Latin America, Western Europe, South Asia, East Asia, Eastern Europe and Middle East & Africa.
The global substance use disorder treatment market is estimated at a value of USD 40.3 billion in 2024.
Revenue of substance use disorder treatment market increased at 4.5% CAGR between 2019 and 2023.
Cipla Limited, Intas Biopharmaceuticals, Purdue Pharma L.P. and Orexo AB are some of the key players in this market.
India is projected to ascend at a CAGR of 5.1% throughout 2034.
The alcohol abuse treatment segment held a share of 51.5% in 2023.
1. Executive Summary
2. Industry Introduction, including Taxonomy and Market Definition
3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments
4. Global Market Demand Analysis 2019 to 2023 and Forecast 2024 to 2034, including Historical Analysis and Future Projections
5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034
5.1. Type
5.2. Treatment
6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Type
6.1. Alcohol Abuse Treatment
6.2. Nicotine Abuse Treatment
6.3. Drug Abuse Treatment
7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Treatment
7.1. Detoxification
7.2. Counselling & Behavioural Therapy
7.3. Medication
7.4. Support Group
8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region
8.1. North America
8.2. Latin America
8.3. Western Europe
8.4. South Asia
8.5. East Asia
8.6. Eastern Europe
8.7. Middle East & Africa
9. North America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
10. Latin America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
11. Western Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
12. South Asia Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
13. East Asia Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
14. Eastern Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
15. Middle East & Africa Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
16. Sales Forecast 2024 to 2034 by Type and Treatment for 30 Countries
17. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard
18. Company Profile
18.1. Cipla Limited
18.2. Intas Biopharmaceuticals
18.3. Allergan plc
18.4. Alkermes plc.
18.5. Indivior plc
18.6. Noramco
18.7. Mallinckrodt plc
18.8. BioCorRx Inc.
18.9. Glenmark Pharmaceuticals Ltd.
18.10. Dr. Reddy’s Laboratories
18.11. Purdue Pharma L.P.
18.12. Orexo AB
Explore Healthcare Insights
View Reports
Substance Use Disorder Treatment Market
